DEEN
Knowledge · Natural substances

Psilocybin (Magic Mushrooms)

Psilocybin is the active substance in magic mushrooms and alters perception, mood and thinking for a few hours.

Last updated:

1. What Is Psilocybin (Magic Mushrooms)?

Psilocybin is the active substance in so-called magic mushrooms. These mushrooms belong mainly to the genus Psilocybe. In the body, psilocybin is converted to psilocin. Psilocin binds to serotonin receptors in the brain, especially at the 5-HT2A receptor. As a result, perception, mood and thinking change strongly for a few hours.

2. Where Is It Found, and What Is It Made From?

Psilocybin is found in more than a hundred mushroom species worldwide. The content varies greatly. For studies, it is usually produced artificially and given in precisely dosed capsules. In addition, there are dried mushrooms and mushroom preparations.

3. What Does Psilocybin (Magic Mushrooms) Do? What Research Shows

AreaState of researchStudies
Depressionwell studied, mostly positive154
Anxiety and distress in serious illnessseveral indications68
Addiction: alcohol and smokingwell studied, mostly positive48
Obsessive-compulsive and eating disorderswell studied, mostly positive19
Memory, dementia and Alzheimer's diseasestill unclear27
Headache and migrainefirst indications16
Other outcomesseveral indications193

Depression

In depression, several controlled studies (with a comparison group) showed an improvement in symptoms 31343740. In two follow-up observations, the improvement persisted for up to twelve months 3346. Other studies found no advantage: after one year 43, in response 32 and compared with the drug escitalopram 38. Even very small doses were not better than a sham drug 42.

Anxiety and Distress in Serious Illness

In end-of-life anxiety, an accompanied psilocybin therapy relieved symptoms more strongly than a sham drug 1630. In a study in life-threatening cancer disease, the anxiety relief persisted for six months 41. Other studies found no difference from the sham drug in anxiety 5456. A review in cancer patients showed mixed results 18.

Addiction: Alcohol and Smoking

In alcohol dependence with depressive symptoms, a small study found more abstinence and fewer drinking days 44. The same study found less craving for alcohol 44. In smoking cessation, after six months more participants were smoke-free with psilocybin than with nicotine patches 36. The studies are small and mostly tested psilocybin together with psychotherapy.

Obsessive-Compulsive and Eating Disorders

In obsessive-compulsive disorder, several controlled studies showed a decrease in obsessive-compulsive symptoms 454952. More participants responded than under niacin 45. After eight weeks of repeated doses, several participants achieved remission 52. The studies are small and usually last only weeks.

Memory, Dementia and Alzheimer's Disease

Studies in people with dementia or Alzheimer's are lacking. In healthy people, psilocybin altered the connections between brain networks 474853. Whether this helps memory or people with dementia has not been investigated. At low doses, attention and impulse control remained unchanged in one study 39. A review, by contrast, describes temporary losses in attention and inhibition 28.

Headache and Migraine

There are only a few very small studies on cluster headache and migraine. In cluster headache, the number of attacks in one study did not differ from a sham drug 51. In migraine, one study showed fewer migraine days than under placebo 55, another no difference 50. Headache occurred as a side effect in several studies 81121.

Other Outcomes

For other outcome measures, the picture is mixed. Reviews describe improvements in quality of life and pain control in cancer patients 1518 as well as in well-being 2029. Suicidal thoughts decreased more in a review than under a comparison treatment 7; another review found this in one of five studies 10. One study reported increased suicidal thoughts on dosing days 32. Nausea, dizziness and increase in blood pressure occurred in several studies 81112.

4. How Was Psilocybin (Magic Mushrooms) Taken in the Studies?

In studies, psilocybin was usually given as an artificially produced capsule, often with psychological support. In addiction, dried mushrooms and truffles were also used. Very small doses were investigated in individual studies on anxiety, memory and pain. Dose, number of sessions and support differ between the studies.

5. Is Psilocybin (Magic Mushrooms) Safe? Side Effects in the Studies

The studies report predominantly mild and temporary side effects such as nausea, headache, dizziness and temporary increase in blood pressure 811121721. Serious side effects and study dropouts were not more frequent in reviews than under a sham drug 2630. Individual studies reported temporary anxiety, suicidal thoughts on dosing days or flashbacks 83235. Tolerability depended on dose and support.

All details with tables and sources: full expert page on Psilocybin (magic mushrooms)

Frequently Asked Questions

Does Psilocybin (magic mushrooms) help with depression? What the studies show

State of research: well studied, mostly positive. There are 154 human studies on this. Sources: 1456

Does Psilocybin (magic mushrooms) help with anxiety and distress in serious illness? What the studies show

State of research: several indications. There are 68 human studies on this. Sources: 8101315

Does Psilocybin (magic mushrooms) help with addiction: alcohol and smoking? What the studies show

State of research: well studied, mostly positive. There are 48 human studies on this. Sources: 231314

Does Psilocybin (magic mushrooms) help with obsessive-compulsive and eating disorders? What the studies show

State of research: well studied, mostly positive. There are 19 human studies on this. Sources: 13162427

Does Psilocybin (magic mushrooms) help with memory, dementia and Alzheimer's disease? What the studies show

State of research: still unclear. There are 27 human studies on this. Sources: 19222325

Does Psilocybin (magic mushrooms) help with headache and migraine? What the studies show

State of research: first indications. There are 16 human studies on this. Sources: 28911

Sources

  1. 1
  2. 2
  3. 3
    Psychedelic-assisted treatment for substance use disorder: A narrative systematic review
    Piper T, Small F, Brown S, Kelleher M, Mitcheson L, Rucker J et al. · 2025
  4. 4
    Psilocybin treatment for symptoms of depression: a living systematic review, meta-analysis, and data resource
    Singleton SP, Sevchik BL, Lahey A, Cuijpers P, Harrer M, Jones MT et al. · 2025
  5. 5
    Psilocybin-assisted therapy for depression: A systematic review and meta-analysis
    Haikazian S, Chen-Li DCJ, Johnson DE, Fancy F, Levinta A, Husain MI et al. · 2023
  6. 6
    Incremental efficacy systematic review and meta-analysis of psilocybin-for-depression RCTs
    Borgogna NC, Owen T, Petrovitch D, Vaughn J, Johnson DAL, Pagano LA et al. · 2025
  7. 7
  8. 8
    Acute Adverse Effects of Therapeutic Doses of Psilocybin: A Systematic Review and Meta-Analysis
    Yerubandi A, Thomas JE, Bhuiya NMMA, Harrington C, Villa Zapata L, Caballero J · 2024
  9. 9
    Psilocybin-assisted therapy for depression: A systematic review and dose-response meta-analysis of human studies
    Perez N, Langlest F, Mallet L, De Pieri M, Sentissi O, Thorens G et al. · 2023
  10. 10
  11. 11
  12. 12
  13. 13
    Mapping Psilocybin-Assisted Therapies: A Scoping Review
    Shore R, Ioudovski P, Goldie C, McKeown S, Dumont E, Queen’s University et al. · 2019
  14. 14
    Therapeutic effect of psilocybin in addiction: A systematic review
    van der Meer PB, Fuentes JJ, Kaptein AA, Schoones JW, de Waal MM, Goudriaan AE et al. · 2023
  15. 15
  16. 16
    Psilocybin-assisted psychotherapy improves psychiatric symptoms across multiple dimensions in patients with cancer
    Petridis PD, Grinband J, Agin-Liebes G, Kinslow CJ, Zeifman RJ, Bogenschutz MP et al. · 2024
  17. 17
  18. 18
    The effects of psilocybin on psychological distress in cancer patients: a systematic review and meta-analysis
    Moshfeghinia R, Mostafavi S, Jazi K, Ghasemi AR, Khosravaninezhad Y, Narayanan S et al. · 2026
  19. 19
    Therapeutic Effects of Low-Dose Psilocybin in Depression and Other Mental Disorders: A Systematic Review
    Meshkat S, Fang H, Sousa-Ho R, Zeifman RJ, Dunkley BT, Reichelt AC et al. · 2026
  20. 20
  21. 21
  22. 22
  23. 23
    Efficacy and safety of psilocybin for the treatment of substance use disorders: A systematic review
    Meshkat S, Malik G, Zeifman RJ, Swainson J, Balachandra K, Reichelt AC et al. · 2025
  24. 24
  25. 25
    Between enhancement and risk: A critical review of psychedelic microdosing
    Totomanova I, Haijen ECHM, Hurks PPM, Ramaekers JG, Kuypers KPC · 2025
  26. 26
  27. 27
    Psilocybin for clinical indications: A scoping review
    Madden K, Flood B, Young Shing D, Ade-Conde M, Kashir I, Mark M et al. · 2024
  28. 28
  29. 29
    The Impact of Psilocybin on Patients Experiencing Psychiatric Symptoms: A Systematic Review of Randomized Clinical Trials
    IsHak WW, Garcia P, Pearl R, Dang J, William C, Totlani J et al. · 2023
  30. 30
    Psilocybin for End-of-Life Anxiety Symptoms: A Systematic Review and Meta-Analysis
    Yu CL, Yang FC, Yang SN, Tseng PT, Stubbs B, Yeh TC et al. · 2021
  31. 31
    Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression
    Goodwin GM, Aaronson ST, Alvarez O, Arden PC, Baker A, Bennett JC et al. · 2022
  32. 32
    Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression: The EPISODE Randomized Clinical Trial
    Mertens LJ, Koslowski M, Betzler F, Brand M, Evens R, Kärtner L et al. · 2026
  33. 33
  34. 34
    Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial
    Raison CL, Sanacora G, Woolley J, Heinzerling K, Dunlop BW, Brown RT et al. · 2023
  35. 35
    Safety pharmacology of acute psilocybin administration in healthy participants
    Straumann I, Holze F, Becker AM, Ley L, Halter N, Liechti ME · 2024
  36. 36
    Psilocybin or Nicotine Patch for Smoking Cessation: A Pilot Randomized Clinical Trial
    Johnson MW, Naudé GP, Hendricks PS, Garcia-Romeu A · 2026
  37. 37
  38. 38
  39. 39
  40. 40
    Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial
    von Rotz R, Schindowski EM, Jungwirth J, Schuldt A, Rieser NM, Zahoranszky K et al. · 2023
  41. 41
  42. 42
  43. 43
    Short-Term and Late-Term Effects of Psilocybin on Symptoms in Major Depression: A Randomized Clinical Trial
    Yngwe H, Plavén-Sigray P, Ekman CJ, Henje E, Berglund A, Tiger M et al. · 2026
  44. 44
    Psilocybin in alcohol use disorder and comorbid depressive symptoms: Results from a feasibility randomized clinical trial
    Luquiens A, Belahda D, Graux C, Igounenc N, Serrand C, Rochefort P et al. · 2025
  45. 45
    Psilocybin for Treatment-Resistant OCD: A Randomized Controlled Trial
    Kelmendi B, Adams T, Ching THW, Grazioplene R, Kichuk S, Fram G et al. · 2026
  46. 46
    Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up
    Gukasyan N, Davis AK, Barrett FS, Cosimano MP, Sepeda ND, Johnson MW et al. · 2022
  47. 47
  48. 48
    Psilocybin Induces Time-Dependent Changes in Global Functional Connectivity
    Preller KH, Duerler P, Burt JB, Ji JL, Adkinson B, Stämpfli P et al. · 2020
  49. 49
    Single-dose (10 mg) psilocybin reduces symptoms in adults with obsessive-compulsive disorder: A pharmacological challenge study
    Pellegrini L, Fineberg NA, O'Connor S, De Souza AMFLP, Godfrey K, Reed S et al. · 2025
  50. 50
  51. 51
  52. 52
    A randomized clinical trial of repeated doses of psilocybin for the treatment of obsessive-compulsive disorder
    Moreno FA, Allen KE, Wiegand CB, Dunne R, Prickett JI, Bayze B et al. · 2026
  53. 53
    Sustained Effects of Low-to-Moderate Doses of Psilocybin on Brain Connectivity
    Bhagavan C, Dandash O, Carter O, Bryson A, Kanaan RA · 2026
  54. 54
    Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial
    Sloshower J, Skosnik PD, Safi-Aghdam H, Pathania S, Syed S, Pittman B et al. · 2023
  55. 55
    Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin
    Schindler EAD, Sewell RA, Gottschalk CH, Luddy C, Flynn LT, Lindsey H et al. · 2021
  56. 56

Every statement on this page carries its evidence tier — proven, plausible or hypothesis — and leads to the original work. The decision in the individual case rests with the practitioner; we provide the connections.

International Health Research · https://ih-research.com/en/knowledge/psilocybin/plain/ · Last updated: 2026-10-15